key: cord-0735059-xlxq96ws authors: Kim, Changho; Kwak, Youngseok; Hwang, Jaechun; Eun, Mi-Yeon title: Spontaneous Intracerebral Hemorrhage in a Patient with Asymptomatic 2019 Novel Coronavirus Disease date: 2020-07-01 journal: J Clin Neurol DOI: 10.3988/jcn.2020.16.3.515 sha: a38f9ff9d166210120c0e2477529071114dc91ef doc_id: 735059 cord_uid: xlxq96ws nan or pneumonia. 1, 3 Because our patient had no symptoms of COVID-19, we could exclude the possibility of secondary stroke related to a medical condition. The mechanism of ICH, in this case, was uncertain. Most previously reported patients with stroke and COVID-19 were elderly and had multiple vascular risk factors, 1,2 whereas our patient was relatively young and had no apparent risk factors for ICH. Besides, ICH occurred shortly after the diagnosis of COVID-19. Thus, we can speculate that spontaneous ICH may occur related to COVID-19. Several explanations could be possible. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) enters the cell through the angiotensinconverting enzyme 2 (ACE2) receptor, 4 which is expressed in vascular endothelial cells and neurons. 5, 6 Reduced expression and dysfunction of ACE2 followed by SARS-CoV-2 infection may impair blood pressure regulation and endothelial function, so that ICH could occur. 7 Additionally, vasculitis by SARS-CoV-2 infection may lead to ICH. However, considering the high prevalence, we could not exclude the possibility that an acute stroke could occur coincidentally in patients with COVID-19. COVID-19 could affect the management process of acute stroke. Before the outbreak of COVID-19, if an patient with acute stroke arrived at the emergency department, brain CT and CT angiography were completed within 15 minutes. In this patient, however, it took 36 minutes. The delay in wearing PPE and use of a negative pressure carrier was inevitable, and these processes successfully decreased the risk of contagion. However, the delay could have been reduced if there was prenotification before the arrival of the patient. Recently, Khosravani et al. 8 introduced the concept of protected code stroke and emphasized the importance of prenotification and PPE in the management of hyperacute stroke. There were other treatment issues in concomitant ICH and COVID-19. Corticosteroids were not recommended in the management of ICH. 9 However, in this patient, corticosteroid was administered because of the possibility of vasculitis by COVID-19 and to avoid surgical treatment. Craniectomy or targeted temperature management was not considered due to the risk of COVID-19 contagion. Because of the concern of virus replication associated with corticosteroid use, we prescribed hydroxychloroquine empirically. Hydroxychloroquine may inhibit the replication of SARS-CoV-2 by interfering with the endosome-mediated viral entry. 10 Recent study showed Fig. 1 . Patient carrier and brain imaging of the patient. A: Negative pressure patient carrier. B and C: Initial brain CT demonstrated ICH in the right external capsule and putamen and ipsilateral intraventricular hemorrhage. D: Brain CT angiography showed no vascular malformation or steno-occlusive lesion in the intracranial cerebral arteries. E and F: Follow-up brain CT on hospital day 14 revealed partial absorption of ICH and intraventricular hemorrhage but aggravation of perilesional edema with mass effect. CT: computed tomography, ICH: intracerebral hemorrhage. A B E C F D Neurologic manifestations of hospitalized patients with coronavirus disease COVID-19 presenting as stroke COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect 2020 SARS-CoV-2 cell entry depends on ACE2 and TM-PRSS2 and is blocked by a clinically proven protease inhibitor Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system Potential neurological symptoms of COVID-19 Protected code stroke: hyperacute stroke management during the coronavirus disease 2019 (COVID-19) pandemic Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Effects of chloroquine on viral infections: an old drug against today's diseases? Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial The authors thank Dr. Ki-Su Park (Department of neurosurgery, Kyungpook National University Chilgok Hospital) for taking care of our patient. The authors have no potential conflicts of interest to disclose.